Alvotech (ALVO) Earnings Call Analysis
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Next earnings call: 2026-08-11
(Q2 2026)
— full calendar
Earnings Reports
-
Alvotech (ALVO) Q1 2026: Product Revenue Down 20% as Facility Upgrades Set Stage for 2027 Growth
May 07, 2026
-
Alvotech (ALVO) Q4 2025: Licensing Revenues Boost Gross Margin to 66% Amid U.S. Regulatory Reset
March 19, 2026
-
Alvotech (ALVO) Q3 2025: FDA Delay Shifts $30M+ Licensing Revenue Into 2026, Margin Recovery Hinges on Launch Execution
November 13, 2025
-
Alvotech (ALVO) Q2 2025: Product Revenue Soars 77% as Margin Focus Drives Biosimilar Expansion
August 14, 2025
-
Alvotech (ALVO) Q1 2025: Raises Revenue Guidance to $700M as Biosimilar Launches Accelerate
July 06, 2025
-
Alvotech (ALVO) Q2 2024: U.S. Humira Order Book Rises 30% as Biosimilar Scale Drives EBITDA Inflection
August 16, 2024
-
Alvotech (ALVO) Q1 2024: 1 Million Humira Biosimilar Orders Signal Inflection in Commercial Scale
May 22, 2024
-
Alvotech (ALVO) Q4 2023: 3-4x Revenue Surge Forecast on Global Biosimilar Launches and Milestones
March 21, 2024